Sangamo Therapeutics (NASDAQ:SGMO) SVP Nathalie Dubois-Stringfellow Sells 345,942 Shares

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) SVP Nathalie Dubois-Stringfellow sold 345,942 shares of the firm’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $0.26, for a total value of $89,944.92. Following the completion of the sale, the senior vice president directly owned 332,769 shares in the company, valued at $86,519.94. This trade represents a 50.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sangamo Therapeutics Trading Down 1.1%

Shares of NASDAQ SGMO opened at $0.26 on Friday. The company has a market cap of $105.64 million, a price-to-earnings ratio of -0.58 and a beta of 1.49. Sangamo Therapeutics, Inc. has a 12 month low of $0.21 and a 12 month high of $0.84. The stock has a 50-day moving average price of $0.34 and a two-hundred day moving average price of $0.44.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.12). The company had revenue of $14.23 million during the quarter, compared to analyst estimates of $40.25 million. Sangamo Therapeutics had a negative net margin of 310.81% and a negative return on equity of 2,662.06%. On average, sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

SGMO has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, February 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. Zacks Research lowered Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. Finally, Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $5.50.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SGMO. World Investment Advisors raised its stake in shares of Sangamo Therapeutics by 88.5% during the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 20,000 shares during the last quarter. R Squared Ltd lifted its holdings in shares of Sangamo Therapeutics by 22.2% during the fourth quarter. R Squared Ltd now owns 147,191 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 26,732 shares during the period. Golden State Equity Partners grew its stake in shares of Sangamo Therapeutics by 6.9% in the third quarter. Golden State Equity Partners now owns 418,943 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 27,000 shares during the last quarter. Wealth Management Associates Inc. grew its stake in shares of Sangamo Therapeutics by 9.1% in the third quarter. Wealth Management Associates Inc. now owns 335,800 shares of the biopharmaceutical company’s stock worth $226,000 after purchasing an additional 28,000 shares during the last quarter. Finally, Oracle Investment Management Inc. increased its holdings in Sangamo Therapeutics by 3.1% in the fourth quarter. Oracle Investment Management Inc. now owns 1,035,742 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 31,018 shares during the period. 56.92% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.